Since neurodegeneration and axonal damage is associated with the subsequent loss of noradrenergic projections, lowered NAT availability as seen in neurodegenerative diseases such as Parkinson’s disease38 and Alzheimer’s disease7, or in the aging human brain39, is explained by this mechanism. Here, BRD2 is linked to neurodegenerative disease.